About
About
HiFiBiO is a clinical stage global biotech pioneering a unique high-resolution translational solution (DIS®) to enhance the probability of success for therapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies.
Our Vision
Pioneer curative immunotherapies for each and every patient
Our Mission
Unlock the curative powers of the immune system with innovative biotherapeutics to improve patient lives
Our Strategy
Advance a sustainable pipeline of breakthrough immunotherapies through single cell driven Drug Intelligence Science (DIS®)
Our Team
Leadership Team
Andrew Griffiths, PhD
Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris
Bradley Bernstein, MD, PhD
Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard
David Weitz, PhD
Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University
Jérôme Bibette, PhD
Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)
Robert Nicol, PhD
Venture Partner at RA Capital Management
Our Team
Leadership Team
Andrew Griffiths, PhD
Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris
Bradley Bernstein, MD, PhD
Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard
David Weitz, PhD
Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University
Jérôme Bibette, PhD
Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)
Robert Nicol, PhD
Venture Partner at RA Capital Management
Our Investors
We are funded by leading VC firms focused on transforming patient care including Mirae Asset, B Capital Group, IDG Capital, Kite Pharma, Sequoia Capital, LYFE Capital, etc
Open-Innovation Partnerships
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS® applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy.